Trinity Biotech plc to Present at the ROTH Capital Partners 23rd Annual OC Growth Stock Conference
DUBLIN, March 9, 2011 /PRNewswire/ — Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced that it will present at the ROTH Capital Partners 23rd Annual OC Growth Stock Conference at the Ritz-Carlton Laguna Beach on Monday, March 14, 2011 at 12:30 pm Pacific Time. Ronan O’Caoimh, Chief Executive Officer, will review the company’s business strategy and recent corporate events.
About Trinity Biotech plc
Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and blood coagulation disorders, and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information please see the company’s website: http://www.trinitybiotech.com.
Contact: Trinity Biotech plc Lytham Partners LLC Joe Diaz, Joe Dorame & Kevin Tansley Robert Blum (353)-1-2769800 602-889-9700 E-mail: email@example.com
SOURCE Trinity Biotech plc